Analysis of selective screening for congenital cytomegalovirus in a secondary hospital: Problems and solutions.

Autor: Marco Sabater A; Servicio de Pediatría, Hospital Universitario Francesc de Borja, Gandía, Valencia, Spain., Sequi Sabater JM; Servicio de Reumatología, Hospital Universitario de La Ribera, Alzira, Valencia, Spain., Gómez Delgado M; Servicio de Pediatría, Hospital Universitario Francesc de Borja, Gandía, Valencia, Spain., Lora Martín A; Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain., Aparisi Climent V; Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain., Sequi Canet JM; Servicio de Pediatría, Hospital Universitario Francesc de Borja, Gandía, Valencia, Spain. Electronic address: sequi_jos@gva.es.
Jazyk: angličtina
Zdroj: Acta otorrinolaringologica espanola [Acta Otorrinolaringol Esp (Engl Ed)] 2024 May-Jun; Vol. 75 (3), pp. 162-168. Date of Electronic Publication: 2024 Jan 12.
DOI: 10.1016/j.otoeng.2023.07.004
Abstrakt: Universal hearing screening offers unique possibilities for detection of congenital deafness as a consequence of congenital cytomegalovirus (CMVc) infection, so its selective study in the case of a failed test could be a non-negligible screening opportunity while other guidelines covering the possibility of universal screening are adopted. The aim of this study is to analyse the possibility of selective screening for CMVc after an altered hearing test in a regional hospital. During the period studied, the results obtained were unsatisfactory, especially in children born outside the hospital of residence, showing an excessive delay in hearing screening in many cases and in the few cases where CMVc screening could be performed, only 30% had the test ordered in a timely manner. The reasons for this are varied and the solution is to include selective screening for CMVc in the hearing screening programme. This implies shortening the timing of the hearing screening protocol to allow CMVc testing in saliva or urine (preferably) before 21 days of age and providing screening programmes with the necessary staff and time to perform it properly.
(Copyright © 2023 Sociedad Española de Otorrinolaringología y Cirugía de Cabeza y Cuello. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: